PFE Pfizer Inc.

A.M. Best Affirms Credit Ratings of Blue Whale Re Ltd.

A.M. Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a+” of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable.

The ratings reflect Blue Whale`s strong risk-adjusted capitalization and conservative operating strategy. The ratings also consider the company`s critical and central role, and favorable profile as part of the Pfizer Group, as well as the excellent operations performance. Partially offsetting these positive rating factors are Blue Whale`s very large gross and net underwriting exposures to property losses, and its dependence on reinsurance.

Blue Whale is a single-parent captive of Pfizer Inc. (Pfizer) [NYSE: PFE], a leading global pharmaceutical company. As Blue Whale (re)insures Pfizer`s global property exposures, it plays an important role in Pfizer`s overall enterprise risk management and assumes a critical role in protecting the Pfizer Group`s assets. Thus, Blue Whale benefits from Pfizer Group`s extensive risk management and loss control programs.

Blue Whale operates at conservative underwriting leverage levels; however, it provides coverages with extremely large limits, and its gross exposures per loss occurrence are elevated. Although Blue Whale benefits from reinsurance protection, its net retentions remain very substantial. Reinsurance is provided by a large panel of reinsurers, and Blue Whale relies on significant capacity to support its obligations. Therefore, it is heavily dependent on reinsurance. Nevertheless, A.M. Best recognizes the quality of the reinsurers, and the substantial financial resources and support available to the captive as part of the Pfizer Group.

Blue Whale’s ratings and outlooks could be upgraded if the parent’s and company’s operating performance improves, and risk-adjusted capital remains supportive of the ratings. Negative rating impact could occur if underwriting performance declines and demonstrates volatility, impacting earnings and capitalization negatively over time. Negative rating impact also could occur if a material shift in risk profile undermines the company’s stability and profitability. Additionally, negative rating impact could occur if the parent’s credit profile deteriorates.

A.M. Best remains the leading rating agency of alternative risk transfer entities, with more than 200 such vehicles rated in the United States and throughout the world. For current Best’s Credit Ratings and independent data on the captive and alternative risk transfer insurance market, please visit www.ambest.com/captive.

This press release relates to Credit Ratings that have been published on A.M. Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see A.M. Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Understanding Best’s Credit Ratings.

A.M. Best is the world’s oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com.

Copyright © 2017 by A.M. Best Rating Services, Inc. and/or its subsidiaries. ALL RIGHTS RESERVED.

EN
27/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pfizer Inc.

Moody's Ratings assigns A2 rating to Pfizer's subsidiary notes offerin...

Moody's Ratings ("Moody's") assigned a A2 rating to the proposed euro-denominated senior unsecured notes offering by Pfizer Netherlands International Finance B.V. (PNIF BV), a wholly-owned subsidiary of Pfizer Inc. (Pfizer). We also assigned a stable outlook to PNIF BV. The A2 rating assigned to P...

Research Team ACF
  • Research Team ACF

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

Pelham Smithers
  • Pelham Smithers

PSA Healthcare / Pharma: Pfizer GLP-1 Drug Failure Puts Light on Upcom...

Pelham Smithers sees the Pfizer news as positive for Chugai and also draws attention to Nxera.

 PRESS RELEASE

Pfizer Invites Public to View and Listen to Webcast of April 29 Confer...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. Participants are advised to re...

 PRESS RELEASE

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Hea...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. The transcript and webcast replay of the discussion will be made available on our web site at within 24 hours after the end of the live discussion a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch